Latest News - Bonti

Thursday, August 02, 2018

Bonti’s Novel Neurotoxin Shines in Early Study of Scar Reduction After Mohs Surgery

Topline results from Bonti’s SHINE-1 Phase 2a clinical trial suggest that its novel neurotoxin is safe and likely effective for scar reduction following Mohs surgery. EB-001, the active ingre…

Read the full story

Monday, February 12, 2018

Dr. Jacob Chacko Joins Bonti’s Board of Directors

Jacob Chacko, MD has joined Bonti’s Board of Directors. Dr. Chacko has served as the Chief Financial Officer of Ignyta, Inc. since May 2014. At Ignyta, he leads multiple functions, including …

Read the full story

Thursday, February 08, 2018

Bonti Takes Aim at Scar Reduction with Shine Clinical Program

Bonti has begun their SHINE (Scar Healing Improvement with Neurotoxin E) clinical program, aimed at scar reduction using its novel neurotoxin. EB- 001 is a novel botulinum neurotoxin serotype …

Read the full story